Masoprocol |
|
| Trade names | Actinex |
|---|
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
|---|
Routes of administration | Topical |
|---|
| ATC code | |
|---|
|
| Bioavailability | Very low |
|---|
|
4-[(2R,3S)-4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol
|
| CAS Number | |
|---|
| PubChem CID | |
|---|
| IUPHAR/BPS | |
|---|
| DrugBank | |
|---|
| ChemSpider | |
|---|
| UNII | |
|---|
| ChEBI | |
|---|
| ChEMBL | |
|---|
| CompTox Dashboard (EPA) | |
|---|
| ECHA InfoCard | 100.044.172 |
|---|
|
| Formula | C18H22O4 |
|---|
| Molar mass | 302.370 g·mol−1 |
|---|
| 3D model (JSmol) | |
|---|
Oc1ccc(cc1O)C[C@H](C)[C@H](C)Cc2ccc(O)c(O)c2
|
InChI=1S/C18H22O4/c1-11(7-13-3-5-15(19)17(21)9-13)12(2)8-14-4-6-16(20)18(22)10-14/h3-6,9-12,19-22H,7-8H2,1-2H3/t11-,12+ YKey:HCZKYJDFEPMADG-TXEJJXNPSA-N Y
|
N Y (what is this?) (verify) |
Masoprocol is an antineoplastic drug used to treat skin growths caused by sun exposure. It is the meso form of nordihydroguaiaretic acid that is taken by mouth. The substance is being studied in the treatment of prostate cancer.
Masoprocol is also called NDGA, and Actinex.
Mechanism
Nordihydroguaiaretic acid is an antioxidant, and it may block certain enzymes needed for tumor growth.
It is a lipoxygenase inhibitor.[1]
References
External links
Intracellular chemotherapeutic agents / antineoplastic agents (L01) |
|---|
SPs/MIs (M phase) | | Block microtubule assembly | |
|---|
| Block microtubule disassembly |
- Taxanes (Cabazitaxel
- Docetaxel#
- Larotaxel
- Ortataxel†
- Paclitaxel#
- Tesetaxel)
- Epothilones (Ixabepilone)
|
|---|
|
|---|
DNA replication inhibitor | DNA precursors/ antimetabolites (S phase) | | Folic acid | |
|---|
| Purine | |
|---|
| Pyrimidine |
- DNA polymerase inhibitor (Cytarabine# +daunorubicin)
|
|---|
| Deoxyribonucleotide | |
|---|
|
|---|
Topoisomerase inhibitors (S phase) | | I |
- Camptotheca (Belotecan
- Camptothecin
- Cositecan†
- Etirinotecan pegol†
- Exatecan
- Gimatecan
- Irinotecan#
- Lurtotecan‡
- Rubitecan‡
- Silatecan§
- Topotecan)
|
|---|
| II | |
|---|
| II+Intercalation | |
|---|
|
|---|
Crosslinking of DNA (CCNS) | | Alkylating | |
|---|
| Platinum-based | |
|---|
| Nonclassical | |
|---|
| Intercalation | |
|---|
|
|---|
|
|---|
| Photosensitizers/PDT | |
|---|
| Other | | Enzyme inhibitors |
- FI (Tipifarnib§)
- CDK inhibitors (Abemaciclib
- Alvocidib†
- Palbociclib
- Ribociclib
- Seliciclib†)
- PrI
- PhI (Anagrelide)
- IMPDI (Tiazofurin§)
- LI (Masoprocol)
- PARP inhibitor (Fuzuloparib
- Niraparib +abiraterone acetate
- Olaparib
- Rucaparib)
- HDAC (Belinostat
- Entinostat
- Panobinostat
- Romidepsin
- Vorinostat)
- PIKI (Pi3K) (Alpelisib
- Copanlisib‡
- Duvelisib
- Idelalisib
- Inavolisib
- Umbralisib‡)
- IDH (Enasidenib
- Ivosidenib
- Olutasidenib
- Vorasidenib)
|
|---|
| Receptor antagonists | |
|---|
| Other/ungrouped |
- Adagrasib
- Aflibercept
- Arsenic trioxide# (Realgar/Indigo naturalis#)
- Asparagine depleters (Asparaginase#/Pegaspargase)
- Axicabtagene ciloleucel
- Belzutifan
- Bexarotene
- Brexucabtagene autoleucel
- Calaspargase pegol
- Celecoxib
- Ciltacabtagene autoleucel
- Darinaparsin
- Demecolcine
- Denileukin diftitox
- Eflornithine
- Elesclomol§
- Elsamitrucin
- Epacadostat
- Eribulin
- Estramustine
- Glasdegib
- Idecabtagene vicleucel
- Idroxioleic acid
- Imetelstat
- Lifileucel
- Lisocabtagene maraleucel
- Lonidamine
- Lucanthone
- Lurbinectedin
- Mitoguazone
- Mitotane
- Nadofaragene firadenovec
- Navitoclax
- Nirogacestat
- Obecabtagene autoleucel
- Oblimersen†
- Omacetaxine mepesuccinate
- Para-toluenesulfonamide
- Pelabresib
- Plitidepsin
- Retinoids (Alitretinoin
- Tretinoin#)
- Selinexor
- Sitimagene ceradenovec
- Sotorasib
- Tabelecleucel
- Tagraxofusp
- Talimogene laherparepvec
- Tazemetostat
- Tebentafusp
- Tiazofurine
- Tigilanol tiglate
- Tisagenlecleucel
- Trabectedin
- Veliparib
- Venetoclax
- Verdinexor
- Vosaroxin
|
|---|
|
|---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|